Abrocitinib treatment for children 6 to under 12 with moderate-to-severe eczema

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Children who meet the entry criteria are randomly assigned to receive either abrocitinib or a matching placebo for 16 weeks, with the whole study lasting about 24 weeks. Caregivers and participants complete electronic diaries and questionnaires and wear a wrist device to measure scratching; clinic visits include physical exams, laboratory tests, and vital signs. Eligible participants have chronic moderate-to-severe atopic dermatitis with prior inadequate response to topical therapy and must weigh at least 15 kg. The study is placebo-controlled and double-arm to compare symptom and safety outcomes between the drug and placebo groups.

Why it matters

Who can join: the full rules

Inclusion Criteria Children aged 6 to \<12 years at the time of informed consent/assent.

• No contraception methods are required for male participants. Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants.

Disease Characteristics:

Participants who meet all of the following AD criteria:

* A documented diagnosis of chronic AD for at least 1 year prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria\[19\]; and
* A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA ≥10%, vIGA ≥3, EASI ≥16, and WI-NRS ≥4); and
* Documented history (within 6 months of the screening visit) of inadequate response to treatment with topical medical therapy for AD (eg, TCS and TCI), for at least 4 weeks and are candidates for systemic therapy

Other Inclusion Criteria:

Body weight ≥15 kg

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

Medical Conditions:

Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

If the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.

Have any of the following medical conditions:

* Infections:

  * Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (Baseline) or have superficial skin infections within 1 week of Day 1.
  * History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day 1.
  * Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.
  * Infection with HIV, hepatitis B, and/or hepatitis C
  * Evidence of active TB or inadequately treated latent TB.
* Skin Conditions:

  \- Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment.
* Other Conditions:

  * Documented history of skeletal dysplasia.
  * Documented history of retinal detachment.
  * History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction.
  * Prior history of leukemia, lymphoma, sarcoma or any other malignancy.
  * Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.
  * Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study.

Prior/Concomitant Therapy:

Prior treatment with a systemic JAK inhibitor for AD. Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention.

Concomitant use of strong inhibitors and inducers of CYP2C19 enzymes, strong inducers of CYP2C9 enzymes, P-gp substrates with narrow therapeutic index and sensitive CYP2C19 substrates is not allowed in the study.

Prior/Concurrent Clinical Study Experience:

Previous administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day 1.

Where it's running

• Cahaba Dermatology & Skin Health Center, LLC
  Birmingham, Alabama, United States Recruiting
• Arkansas Research Trials
  North Little Rock, Arkansas, United States Recruiting
• Investigational Drug Service - Rady Childrens Hospital-San Diego
  San Diego, California, United States Recruiting
• University of California, San Diego/Rady Children's Hospital-San Diego; Pediatric & Adolescent Derm
  San Diego, California, United States Recruiting
• Solutions Through Advanced Research
  Jacksonville, Florida, United States Recruiting
• Ada West Research
  Meridian, Idaho, United States Recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How exposure to heavy metals, nanoparticles, and emerging contaminants relates to allergic skin and systemic metal reactions

  This project will test whether adults with allergic contact dermatitis or systemic metal allergies have different levels of heavy metals, nanoparticles, and related blood and urine markers compared with healthy adults.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Bologna and 1 other locations · NCT06529913

• Learning about Abrocitinib for treating moderate to severe atopic dermatitis in adults

  This study is testing if taking Abrocitinib daily can safely help adults with moderate to severe atopic dermatitis feel better over two years.

  Recruiting at 30 sites Pfizer · Amiens, Somme and 29 other locations · NCT05689151

• Digital mindfulness app for teens with eczema

  Teens with moderate to severe eczema try a digital mindfulness app to see if it helps control symptoms and improve quality of life.

  Recruiting at 2 sites Weill Medical College of Cornell University · New York, New York and 1 other locations · NCT07746427

• Camoteskimab in adults with moderate-to-severe atopic dermatitis

  This trial tests different doses of camoteskimab versus placebo to see if it helps adults with moderate-to-severe atopic dermatitis who have not fully responded to standard treatments.

  Recruiting at 31 sites Phase 2 Apollo Therapeutics Ltd · Birmingham, Alabama and 84 other locations · NCT07599813

• ARQ-234 single and multiple rising dose testing

  This will test different single and repeated doses of ARQ-234 to see if they are safe and how the drug behaves in healthy adults and adults with moderate-to-severe atopic dermatitis.

  Recruiting at 7 sites Phase 1 Arcutis Biotherapeutics, Inc. · Miami, Florida and 6 other locations · NCT07453602

• Low-sodium diet and salt tablets to see if eczema improves

  This study tests whether a low-sodium diet can lessen eczema symptoms in adults with atopic dermatitis, using a cross-over design with sodium tablets and placebo to see if salt intake changes skin sodium and severity.

  Recruiting at 2 sites Phase 4 University of California, San Francisco · San Francisco, California and 1 other locations · NCT07447063

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.